An observational study in Melanoma, Breast Cancer and Oncology, sponsored by N.N. Petrov National Medical Research Center of Oncology. Active, not recruiting at 1 site in Russia. Open to participants aged 0 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by N.N. Petrov National Medical Research Center of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Melanoma with a site in Russia — 3 open to participants now, 9 under way, 4 of them phase 3. Melanoma · Russia.
Among the 22 studies in Melanoma with a site in Russia, this one is one of 5 that started in 2023, is the only observational one, and was the 16th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →3 of the 22 studies in Melanoma with a site in Russia are open now. Recruiting first, the newest first:
EuroCityClinic LLC · Sites in Russia
Ages 18+
BioInvent International AB · Sites in Russia, United States, Denmark and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Russia, United States, Argentina and 12 more countries
Ages 18–100
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 0 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 11 · Phase 4 1
First in 2006; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 300 across the 21 interventional studies, 100,000 across the 1 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 22 have an industry lead sponsor. The 10 most frequent:
N.N. Petrov National Medical Research Center of Oncology is the lead sponsor of 27 studies on the registry; 15 are open to participants now.
N.N. Petrov National Medical Research Center of Oncology has 5 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
2 of the studies in Melanoma with a site in Russia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05751928Phase 3BiocadA Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | 2027-01 |
| NCT06043947N.N. Petrov National Medical Research Center of OncologySurvival Monitoring in Russian Cancer Registries | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Melanoma with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.
The main sources of cancer incidence data in Russia are population-based cancer registries (PBCR). National recommendations guide the content of corresponding variables stored in PBCRs. Data were collected for the following regions: Arkhangelsk Oblast and Nenets Autonomous Okrug (combined), Republic of Karelia, Komi Republic, Vologda Oblast, Kaliningrad Oblast, Leningrad Oblast, Murmansk Oblast, Novgorod Oblast, Pskov Oblast, and St. Petersburg. Quality assessment procedures will be applied to the population-based cancer registries (PBCRs) datasets. Essential variables will be extracted following the recommended list of ENCR/IACR.
The list of variables consists of two classes: original variables present in PBCRs datasets and synthetic variables calculated based on the original variables. "IARC/IACR Tools for Cancer Registries" (IARC tools) software was used for the data cleaning, conversion to ICD-O-3, and multiple primaries assessment. Duplicates were removed by applying IARC/IACR/ENCR multiple primary rules. The analysis is limited to twenty years: 2000 - 2021.
The Federal State Statistics Service (FSSS) is the primary regional and national mortality data source. However, the raw data from this source has several drawbacks. The main problem is the absence of the distribution of persons with undetermined ages and/or causes of death. The data sets for this research are obtained from the Russian Fertility and Mortality Database (RFMD) of the Center for Demographic Research of the New Economic School. The RFMD database is based on the FSSS data but has a higher data quality due to the redistribution of deaths with the abovementioned characteristics. This source's population and mortality data contained the following variables: region, year, sex, age (5-year age groups from 0 to 85+), and cause of death.
Population data was obtained from the same source. The data were based on the 1989, 2002 and 2010 population censuses. It has been extrapolated to other years using annual statistics on mortality and births.
Cancer patient population, that were diagnosed and registered in regions covered by PBCR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Net survival
Net survival computed using Pohar-Perme method.
Time frame: From the date of diagnosis to the date of death (up to 10 years)
Cause-specific survival
Rates calculated using Kaplan-Maier method.
Time frame: From the date of diagnosis to the date of death (up to 10 years)
Plan to share: Undecided
Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.
Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 40 months is below that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
N.N. Petrov National Medical Research Center of Oncology